Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
2063 results about "Carrier protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Carrier proteins facilitate the diffusion of different molecules, while channel proteins are involved in the movement of ions, small molecules, or macromolecules, such as another protein, across a biological membrane. Carrier proteins are integral/intrinsic membrane proteins; that is they exist within and span the membrane across which they transport substances. The proteins may assist in the movement of substances by facilitated diffusion or active transport. These mechanisms of movement are known as carrier-mediated transport. Each carrier protein is designed to recognize only one substance or one group of very similar substances. Research has correlated defects in specific carrier proteins with specific diseases.
Multivalent pneumococcal polysaccharide-protein conjugate composition
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
Owner:WYETH LLC
Multivalent pneumococcal polysaccharide-protein conjugate composition
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.
Owner:WYETH LLC
Multivalent pneumococcal polysaccharide-protein conjugate composition
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 1 polysaccharide covalently linked to a carrier protein, the method including partial de-O-acetylation of the polysaccharide by mild hydrolysis in an alkaline pH buffer.
Owner:WYETH LLC
Multivalent pneumococcal polysaccharide-protein conjugate composition
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 3 polysaccharide covalently linked to a carrier protein, the method including periodic acid oxidation of the polysaccharide in the presence of bivalent cations.
Owner:WYETH LLC
Collagen binding protein compositions and methods of use
InactiveUS6288214B1Prevent and lessen adhesionReduce adhesionAntibacterial agentsPeptide/protein ingredientsPassive ImmunizationsCarrier protein
Disclosed are the cna gene and cna-derived nucleic acid segments from Staphylococcus aureus, and DNA segments encoding cna from related bacteria. Also disclosed are Col binding protein (CBP) compositions and methods of use. The CBP protein and antigenic epitopes derived therefrom are contemplated for use in the treatment of pathological infections, and in particular, for use in the prevention of bacterial adhesion to Col. DNA segments encoding these proteins and anti-(Col binding protein) antibodies will also be of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of bacterial colonization in an animal such as a human. These DNA segments and the peptides derived therefrom are contemplated for use in the preparation of vaccines and, also, for use as carrier proteins in vaccine formulations, and in the formulation of compositions for use in the prevention of S. aureus infection.
Owner:TEXAS A&M UNIVERSITY
Methods and compositions for treating pulmonary hypertension
InactiveUS20100166869A1Pulmonary hypertension is delayedReduce pressureBiocidePowder deliveryNanoparticleCarrier protein
The present invention features methods for treating, stabilizing, preventing, and / or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and / or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and / or nanoparticles that comprise a carrier protein and a taxane (e.g. paclitaxel) or a derivative thereof.
Owner:ABRAXIS BIOSCI LLC
Methods for protein labeling based on acyl carrier protein
InactiveUS7666612B2Cell receptors/surface-antigens/surface-determinantsSugar derivativesCoenzyme A biosynthesisCarrier protein
A method for labeling acyl carrier protein (ACP) fusion proteins with a wide variety of different labels is disclosed. The method relies on the transfer of a label from a coenzyme A type substrate to an ACP fusion protein using a holo-acyl carrier protein synthase (ACPS) or a homologue thereof. The method allows detecting and manipulating the fusion protein, both in vitro and in vivo, by attaching molecules to the fusion proteins that introduce a new physical or chemical property to the fusion protein. Examples of such labels are, among others, spectroscopic probes or reporter molecules, affinity tags, molecules generating reactive radicals, cross-linkers, ligands mediating protein-protein interactions or molecules suitable for the immobilization of the fusion protein.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
ActiveUS20070117744A1Improve stabilityImprove filtering effectBiocideNanotechSide effectMicrobial agent
The present invention provides compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, and an antimicrobial agent, wherein significant microbial growth is inhibited in the composition. The amount of the antimicrobial agent in the composition may be below the level that induces a toxicological effect or at a level where a potential side effect can be controlled or tolerated. Also provided are compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, a sugar, and optionally an antimicrobial agent. Methods of using the compositions are also provided.
Owner:ABRAXIS BIOSCI LLC
High-efficiency 14-valent pneumococcal conjugate vaccine
InactiveCN101590224AEffective protectionAntibacterial agentsBacterial antigen ingredientsCoccidiaHaemophilus
The invention relates to a high-efficiency 14-valent pneumococcal conjugate vaccine, which is formed by coupling and combining capsular polysaccharide extracted from fourteen types of serotype pneumococcuses and carrier protein; the fourteen types of the serotype pneumococcuses are 1, 2, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F; and the carrier protein is diphtherin non-toxic mutated protein CRM197, tetanus toxin protein and influenza haemophilus protein D. Compared with the prior pneumococcal conjugate vaccine, the high-efficiency 14-valent pneumococcal conjugate vaccine has the advantages that: (1) the cross-protection rate of the pneumococcuses of fourteen serotypes (1, 2, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F) reaches more than 90 percent; and (2) the high-efficiency 14-valent pneumococcal conjugate vaccine can generate effective protection on senior citizens which are susceptible to pneumonia and is suitable for children under two years old.
Owner:广州精达医学科技有限公司
Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
ActiveUS7771751B2Improve stabilityImprove filtering effectOrganic active ingredientsPowder deliverySide effectMicrobial agent
The present invention provides compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, and an antimicrobial agent, wherein significant microbial growth is inhibited in the composition. The amount of the antimicrobial agent in the composition may be below the level that induces a toxicological effect or at a level where a potential side effect can be controlled or tolerated. Also provided are compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, a sugar, and optionally an antimicrobial agent. Methods of using the compositions are also provided.
Owner:ABRAXIS BIOSCI LLC
Injectable vaccines against multiple meningococcal serogroups
ActiveUS20070082014A1Pharmaceutical delivery mechanismDepsipeptidesStreptococcus pneumoniaeSalmonella serotype typhi
An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and / or are oligosaccharides, and wherein (i) the composition comprises <50 mug meningococcal saccharide per dose, and / or (ii) the composition further comprises an antigen from one or more of: (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and / or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
ActiveUS20110195086A1Antibacterial agentsBacteria material medical ingredientsConjugate vaccineDisease
The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) conjugated to a carrier protein, preferably CRM197. The immunogenic composition, preferably formulated as a vaccine on an aluminum-based adjuvant, provides broad coverage against pneumococcal disease, particularly in infants and young children.
Owner:MERCK SHARP & DOHME LLC
Globo h and related Anti-cancer vaccines with novel glycolipid adjuvants
ActiveUS20100136042A1Shrink tumorInhibit tumor growthOrganic active ingredientsSugar derivativesDendritic cellAdjuvant
Owner:ACAD SINIC
Methods and compositions for inducing autoimmunity in the treatment of cancers
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Nanoparticle formulations and uses thereof
InactiveUS20090263483A1Improve bindingGood curative effectBiocideOrganic active ingredientsDiseaseNanoparticle
The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.
Owner:ABRAXIS BIOSCI LLC
Polyepitope carrier protein
InactiveUS6855321B1Facilitate subsequent purificationAccurate supervisionAntibacterial agentsVirusesCarrier proteinCD4 antigen
The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines arm particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.
Owner:NOVARTIS AG
Nanoparticle comprising rapamycin and albumin as anticancer agent
The present invention features methods for treating, stabilizing, preventing, and / or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
Owner:ABRAXIS BIOSCI LLC
Pneumococcal Polysaccharide Conjugate Vaccine
The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Novel Bioactive Lipid Derivatives, and Methods of Making and Using Same
InactiveUS20070281320A1Minimize the possibilityImmunoglobulins against animals/humansCulture processPolyethylene glycolCarrier protein
Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described.
Owner:APOLLO ENDOSURGERY INC
Methods and compositions for treating recurrent cancer
The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.
Owner:ABRAXIS BIOSCI LLC
Multivalent pneumococcal polysaccharide-protein conjugate composition
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 3 polysaccharide covalently linked to a carrier protein, the method including periodic acid oxidation of the polysaccharide in the presence of bivalent cations.
Owner:WYETH LLC
Compositions that include hemagglutinin, methods of making and methods of use thereof
InactiveUS20070224205A1Avoid serious illnessAvoid deathSsRNA viruses negative-senseSsRNA viruses positive-senseHemagglutininArginine
Compositions comprise a flagellin component or a Toll-like Receptor agonist component that is at least a portion of a flagellin or a Toll-like Receptor agonist, wherein the flagellin component or Toll-like Receptor agonist component includes at least one cysteine residue and whereby the flagellin component or Toll-like Receptor agonist component activates a Toll-like Receptor 5 or Toll-like Receptor. Compositions comprise a flagellin component that is at least a portion of a flagellin, wherein at least one lysine of the flagellin component has been substituted with at least one arginine, serine and histidine, whereby the flagellin component activates Toll-like Receptor 5. Compositions can further include an antigen, such as an influenza antigen, a flavivirus antigen, a pathogen-related antigen, a bacterial capsular antigen and a carrier protein. The compositions are used to stimulate an immune response and a protective immune response in a subject.
Owner:VAXINNATE
Multivalence pneumococcus capsular polysaccharide-protein conjugate composition and preparation method thereof
ActiveCN103656631AImprove adsorption capacityImprove stabilityAntibacterial agentsBacterial antigen ingredientsConjugate vaccineDisease
The invention provides a multivalence pneumococcus capsular polysaccharide-protein conjugate composition and a preparation method thereof. The conjugate composition is prepared from capsular polysaccharides of pneumococcus of 24 different serotypes and a carrier protein in a covalence connection manner, wherein the 24 different serotypes are 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. The conjugate composition is good in adsorption effect and stability, has multiple immunogenicity and protection properties aiming at invasion of pneumococcus of the 24 serotypes, and is superior to the low-valence pneumonia composition in the market, and the immune response is higher than that of uncombined compositions. By inoculating a multivalence pneumococcus capsular polysaccharide conjugate vaccine prepared from the conjugate composition, the inoculation injection times can be reduced, the immunization procedure can be simplified, and meanwhile human beings and animals can be effectively prevented from diseases resulted from the pneumococcus of the 24 serotypes, and the conjugate composition is wide in coverage range and good in immune effect.
Owner:SINOVAC RES & DEV
Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
ActiveUS20070141077A1Prevention and reduction of severityAntibacterial agentsBacterial antigen ingredientsCarrier proteinImmunogenicity
Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesin carrier protein. Such immunogenic compositions are used to immunize against diseases caused by Staphylococcal aureus, Staphylococcal epidermidis or other nosocomial pathogens.
Owner:WYETH HOLDINGS CORP
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
InactiveUS20100209450A1Antibacterial agentsSenses disorderConjugate vaccineStreptococcus pneumoniae capsular polysaccharide
The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid. Methods of making and uses thereof are also described.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Drug residue competition-type quantum dot-labeled immunochromatography assay test-strip and observation device thereof
The invention provides a drug residue competition-type quantum dot-labeled immunochromatography assay test-strip / detection card and an observation device thereof, comprising the following preparation steps of coating the antibody of quantum dot-labeled drug molecule on a fiberglass film, coating the drug-molecular-carrier protein coupler and second antibody on a pyroxylin film or a cellulose acetate film respectively to form a detection belt and a quality control belt; preparing the immunochromatography assay test-strip from the fiberglass film and the pyroxylin film or the cellulose acetate film on a polyester or plastic plate, and assembling a shell. The quantum dots of the detection belt and the quality control belt on the test-strip is triggered by the ultraviolet LED source of the observation device, and the change of the fluorescent intensity of the observation belt and the quality control belt is observed, thus being capable of quantitatively analyzing the content of the drug molecule in the sample. The invention has simple operation, high sensitiveness and quick quantification, is suitable for detecting the drug residue in the food and can be widely applied to the customhouse, airport, health supervising department, household and the like.
Owner:CHINA JILIANG UNIV
15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
Owner:MERCK SHARP & DOHME LLC
Form-specific antibodies for nag-1 (mic-1, gdf-15), h6d and other tgf-beta subfamily and heart disease and cancer diagnoses
A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer.
Owner:DETROIT R&D
Nanoparticle comprising rapamycin and albumin as anticancer agent
The present invention features methods for treating, stabilizing, preventing, and / or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
Owner:DESAI NEIL P +2
Methods and compositions for inducing autoimmunity in the treatment of cancers
InactiveUS20030004097A1Sensitive and simple and rapidIncrease concentrationOrganic active ingredientsNanotechAutoimmune responsesCarrier protein
Disclosed are methods and compositions for the prevention and treatment of cancers using lipid-carrier protein conjugate compositions for generating lipid-specific immune responses in an animal. Also disclosed are methods for making phosphatidylserine conjugate compositions and their formulation for use in a variety of pharmaceutical applications including the detection and treatment of a variety of cancers and related conditions.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com